Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm, Forma Therapeutics Partner to ID Molecular Markers for Preclinical Candidates

NEW YORK (GenomeWeb) – Paradigm and Forma Therapeutics today announced a multiyear partnership to identify predictive response biomarkers and measure pharmacodynamic activity for two of Forma's advanced preclinical candidates.

Paradigm will use its technology to evaluate the potential of molecular markers to predict clinical outcomes, which would enable Forma "to efficiently match our drugs with high-quality molecular assays to realize a personalized approach to cancer drug development," Forma President and CEO Steven Tregay said in a statement.

Through a spokesman, Forma declined to disclose the target and disease indications for the two therapeutic candidates. He added that certain details of the agreement are being finalized, but that for some projects Paradigm's PCDx test will be used, while for others, different assays could be developed.

PCDx is a next-generation sequencing-based cancer test that sequences both DNA and RNA.

Forma will also "be leveraging [Paradigm's] evidence team and biomarker expertise to develop target strategies," the spokesman said. Financial and other terms of the deal were not disclosed.

Last week Paradigm announced it initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.